STOCK TITAN

Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) has achieved several significant milestones:

  • Completed the first export of GMP-validated MDMA capsules to Australia for PTSD treatment under the Authorised Prescriber Scheme
  • Received permits for psilocybin shipment to New Zealand for a pilot study
  • Influenced Australian regulatory framework for MDMA and psilocybin manufacturing requirements
  • Closed the first tranche of a non-brokered private placement, raising CAD$538,999.80

These developments position Optimi as a leader in the psychedelics pharmaceutical industry, with a focus on MDMA and psilocybin for mental health treatments.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) ha raggiunto importanti traguardi:

  • Completato il primo export di capsule di MDMA validate GMP in Australia per il trattamento del PTSD secondo il Programma degli Operatori Autorizzati
  • Ricevuti i permessi per la spedizione di psilocibina in Nuova Zelanda per uno studio pilota
  • Influenza sul quadro normativo australiano per i requisiti di produzione di MDMA e psilocibina
  • Chiusura della prima tranche di un collocamento privato non mediato, raccogliendo CAD$538.999,80

Questi sviluppi posizionano Optimi come leader nell'industria farmaceutica degli psichedelici, con un focus su MDMA e psilocibina per i trattamenti della salute mentale.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) ha alcanzado varios hitos importantes:

  • Completada la primera exportación de cápsulas de MDMA validadas por GMP a Australia para el tratamiento del PTSD bajo el Esquema de Prescriptores Autorizados
  • Recibidos los permisos para el envío de psilocibina a Nueva Zelanda para un estudio piloto
  • Influenciado el marco regulatorio australiano para los requisitos de fabricación de MDMA y psilocibina
  • Cierre de la primera parte de una colocación privada no mediada, recaudando CAD$538.999,80

Estos desarrollos posicionan a Optimi como un líder en la industria farmacéutica de los psicodélicos, con un enfoque en el MDMA y la psilocibina para tratamientos de salud mental.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF)는 여러 중요한 이정표를 달성했습니다:

  • PTSD 치료를 위한 GMP 인증을 받은 MDMA 캡슐을 호주로 최초 수출 완료
  • 파일럿 연구를 위한 뉴질랜드행 실로시빈 배송 허가 획득
  • MDMA와 실로시빈 제조 요구사항에 대한 호주 규제 프레임워크에 영향
  • 비 브로커 방식의 사모펀드 첫 번째 분할 종료, CAD$538,999.80 모금

이러한 발전은 Optimi를 정신 건강 치료를 위한 MDMA와 실로시빈에 중점을 둔 환각제 제약 산업의 선두주자로 자리매김하게 합니다.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) a réalisé plusieurs étapes importantes :

  • Achevé le premier export de capsules de MDMA validées par la GMP vers l'Australie pour le traitement du PTSD dans le cadre du Schéma des Prescripteurs Autorisés
  • Recevoir des autorisations pour l'envoi de psilocybine en Nouvelle-Zélande pour une étude pilote
  • A influencé le cadre réglementaire australien concernant les exigences de fabrication de MDMA et de psilocybine
  • Clôturé la première tranche d'un placement privé non intermédié, levant CAD$538.999,80

Ces développements positionnent Optimi comme un leader dans l'industrie pharmaceutique des psychédéliques, avec un accent sur le MDMA et la psilocybine pour les traitements de santé mentale.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) hat mehrere bedeutende Meilensteine erreicht:

  • Erster Export von GMP-validierten MDMA-Kapseln nach Australien zur Behandlung von PTSD im Rahmen des Genehmigten Verschreiberschemas abgeschlossen
  • Genehmigungen für psilocybinlieferungen nach Neuseeland für eine Pilotstudie erhalten
  • Einfluss auf den australischen Regulierungsrahmen für die Produktionsanforderungen von MDMA und Psilocybin
  • Abschluss der ersten Tranche einer nicht vermittelten Privatplatzierung, wobei CAD$538.999,80 eingeworben wurden

Diese Entwicklungen positionieren Optimi als führendes Unternehmen in der psychedelischen Pharmaindustrie, mit einem Fokus auf MDMA und Psilocybin zur Behandlung von psychischen Erkrankungen.

Positive
  • Successful export of GMP-validated MDMA capsules to Australia for PTSD treatment
  • Received export permit for psilocybin shipment to New Zealand for research
  • Influenced TGA's regulatory framework for MDMA and psilocybin manufacturing
  • Raised CAD$538,999.80 through first tranche of private placement
  • Expanded international presence in Australia and New Zealand markets
Negative
  • Dilution of existing shareholders due to new share issuance in private placement

Vancouver, British Columbia--(Newsfile Corp. - August 16, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce it has completed the inaugural export of it's GMP-validated MDMA capsules to Australia for the treatment of PTSD, along with a series of notable corporate developments.

MDMA Capsule Export to Australia

The Company is pleased to announce the successful export of its GMP-validated 40mg and 60mg MDMA capsules for the treatment of PTSD under Australia's Authorised Prescriber Scheme. The first cohort of patients is scheduled to begin MDMA-assisted therapy using these capsules in the coming weeks. This milestone marks the start of Optimi's journey in gathering critical Real-World Evidence and Patient-Reported Outcomes for MDMA-assisted therapy in Australian PTSD patients. The export follows the recent acquisition of Optimi's Drug Establishment Licence, a requirement for supplying MDMA capsules to patients in clinical settings worldwide, and was done in partnership with Mind Medicine Australia.

Permits Received for Psilocybin Shipment to New Zealand

Optimi has received the necessary Export Permit from Health Canada for its first shipment of validated GMP natural psilocybin extract to the Mātai Medical Research Institute in New Zealand. The product will be used in a pilot study evaluating the feasibility, acceptability, and safety of administering psychedelic-assisted therapy in healthy volunteers. The insights gained from this trial will inform potential future controlled trials involving Māori patients with methamphetamine use disorder.

Australian Regulatory Framework Influence

Optimi's feedback on GMP manufacturing requirements for MDMA and psilocybin has been adopted by the Therapeutic Goods Administration (TGA) in Australia, underscoring the Company's role in shaping global regulatory standards. As a recognized leader with one of the largest genetic banks of Psilocybe cubensis worldwide, with over 300 strains on-site, Optimi is pleased that the TGA supports Psilocybe cubensis as the "single species of mushroom" to be offered to patients under its regulatory framework.

Closing of First Tranche from Non-Brokered Private Placement

The Company also announces it has closed the first tranche of its non-brokered private placement announced August 7, 2024, by issuing 1,796,666 units (each a "Unit") at CAD$0.30 per Unit for gross proceeds of CAD$538,999.80 (the "Offering").

Each Unit is comprised of one (1) common share in the capital of the Company (each a "Common Share") and one-half of one (1/2) transferable Common Share purchase warrant (each whole warrant a "Warrant"). Each Warrant entitles the holder to acquire one (1) Common Share at CAD$0.40 until August 15, 2026, subject to an accelerated expiry provision, whereby in the event the closing price of the Company's Common Shares on the Canadian Securities Exchange (the "Exchange") exceeds CAD$0.50 for a period of 20 consecutive trading days, at the Company's election, the period within which the Warrants are exercisable, will be reduced and the holders of the Warrants will be entitled to exercise their Warrants for a period of 30 days commencing on the day the Company provides notice, any outstanding Warrants not exercised during the 30 day period will expire. The Company intends to use the net proceeds from the Offering to further commercialize business development opportunities in Australia and around the world, commissioning recently purchased equipment for its GMP production and analytical laboratory, and general working capital. All securities issued under the Offering, including securities issuable on exercise thereof, will be subject to a hold period expiring December 16, 2024, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws. The Offering constituted a "related party transaction" as defined in Multilateral Instrument 61-101 - Protection of Minority Securityholders in Special Transactions ("MI 61-101"), as one related party of the Company acquired an aggregate of 333,333 Units. Following the acquisition Dane Stevens, Chief Marketing Officer and a Director, holds 10,617,232 Common Shares or 11.22% of the Company. The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as the fair market value of the participation in the Offering by the insiders does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101.

For more information about Optimi Health Corp., please contact:
Bill Ciprick, CEO
Telephone: (778) 761-4551

For media inquiries, please contact:
Andrea Mestrovic
Andrea@weareverypolite.com

For investor inquiries, please contact:
Michael Kydd
investors@optimihealth.ca
For more information, please visit www.optimihealth.ca.

About Optimi Health

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a leading psychedelics pharmaceutical manufacturer licensed by Health Canada. Specializing in controlled substances such as botanical psilocybin and MDMA, Optimi is dedicated to supplying safe, top-tier GMP-grade products and APIs to researchers, drug developers, and authorized patients worldwide.

Optimi's facilities in Princeton, British Columbia, are purpose-built to develop proprietary formulations under strict GACP and GMP conditions, ensuring unparalleled quality and reliability. The Company is committed to being the most trusted supplier of safe psychedelic drug candidates globally.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements") that relate to Optimi's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward-Looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220178

FAQ

What is the purpose of Optimi Health's MDMA capsule export to Australia?

Optimi Health's MDMA capsule export to Australia is for the treatment of PTSD under the country's Authorised Prescriber Scheme. This export will help gather Real-World Evidence and Patient-Reported Outcomes for MDMA-assisted therapy in Australian PTSD patients.

What is the significance of Optimi Health's psilocybin shipment to New Zealand?

Optimi Health's psilocybin shipment to New Zealand will be used in a pilot study at the Mātai Medical Research Institute. The study aims to evaluate the feasibility, acceptability, and safety of administering psychedelic-assisted therapy in healthy volunteers, potentially informing future trials for methamphetamine use disorder in Māori patients.

How much did Optimi Health (OPTHF) raise in its recent private placement?

Optimi Health (OPTHF) raised CAD$538,999.80 in the first tranche of its non-brokered private placement by issuing 1,796,666 units at CAD$0.30 per unit.

What is the expiry date for the warrants issued in Optimi Health's (OPTHF) private placement?

The warrants issued in Optimi Health's (OPTHF) private placement expire on August 15, 2026, subject to an accelerated expiry provision if certain conditions are met.

OPTIMI HEALTH CORP

OTC:OPTHF

OPTHF Rankings

OPTHF Latest News

OPTHF Stock Data

15.34M
75.57M
16.52%
0.05%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Garibaldi Highlands